Cargando…

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies

Allopurinol is widely used for hyperuricemia and gouty arthritis, but is associated with cutaneous adverse drug reactions (CADRs). Recently, HLA-B*58:01 allele was identified as a strong genetic marker for allopurinol-induced CADRs in Han Chinese. However, the magnitude of association and diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Ran, Cheng, Yi-ju, Zhu, Li-li, Yu, Lei, Zhao, Xue-ke, Jia, Min, Wen, Chang-hui, Long, Xing-zhen, Tang, Ting, He, Ai-juan, Zeng, Yi-yan, Ma, Zun-feng, Zheng, Zhi, Ni, Mu-zi, Cai, Gong-jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348437/ https://www.ncbi.nlm.nih.gov/pubmed/27835909 http://dx.doi.org/10.18632/oncotarget.13250

Ejemplares similares

HLA-B*58:01 allele is strongly associated with allopurinol-induced severe cutaneous adverse reactions in a Thai population
por: Jantararoungtong, Thawinee, et al.
Publicado: (2014)

HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
por: Sukasem, Chonlaphat, et al.
Publicado: (2016)

Comparison between the HLA-B(∗)58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions
por: Saksit, Niwat, et al.
Publicado: (2017)

Validation of a Rapid, Robust, Inexpensive Screening Method for Detecting the HLA-B(*)58:01 Allele in the Prevention of Allopurinol-Induced Severe Cutaneous Adverse Reactions
por: Nguyen, Dinh Van, et al.
Publicado: (2017)

Allopurinol-induced severe cutaneous adverse reactions: A report of three cases with the HLA-B(*)58:01 allele who underwent lymphocyte activation test
por: Kim, Eun-Young, et al.
Publicado: (2017)

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study
por: Ko, Tai-Ming, et al.
Publicado: (2015)

Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01
por: Huan, Xuelu, et al.
Publicado: (2023)

Allopurinol-Induced Stevens–Johnson Syndrome in Javanese Men With Positive HLA‐B*58:01
por: Ferdiana, Astri, et al.
Publicado: (2022)

HLA-B(*)13:01 as a Risk Allele for Antiepileptic Drugs-Induced Cutaneous Adverse Reactions: Higher Risk for Cross-Reactivity?
por: Min, Fu-Li, et al.
Publicado: (2019)

Predominant HLA Alleles and Haplotypes in Mild Adverse Drug Reactions Caused by Allopurinol in Vietnamese Patients with Gout
por: Van Son, Chu, et al.
Publicado: (2021)

248 HLA-B58 Does not Increase Allopurinol Hypersensitivity among Patients with Hematologic Malignancy
por: Jung, Jae-Woo, et al.
Publicado: (2012)

A prospective study of HLA*B-5801 genotyping in preventing allopurinol- induced severe cutaneous adverse reactions
por: Ko, Tai-Ming, et al.
Publicado: (2014)

Characterization of the novel HLA‐DPA1*02:01:21 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

HLA‐A*24:02 increase the risk of allopurinol‐induced drug reaction with eosinophilia and systemic symptoms in HLA‐B*58:01 carriers in a Korean population; a multicenter cross‐sectional case‐control study
por: Kim, Mi‐Yeong, et al.
Publicado: (2022)

HLA-DRB1∗16:01 and HLA-DQB1∗05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma
por: Wang, Xu, et al.
Publicado: (2021)

Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population
por: Koomdee, Napatrupron, et al.
Publicado: (2017)

The HLA-A*31:01 allele: influence on carbamazepine treatment
por: Yip, Vincent Lai Ming, et al.
Publicado: (2017)

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01
por: Cascella, R, et al.
Publicado: (2015)

Clinical evaluation of a substitute of HLA-B*58:01 in different Chinese ethnic groups
por: Zhang, Xinju, et al.
Publicado: (2018)

HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02
por: Martín, Paloma, et al.
Publicado: (2015)

Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions
por: Wattanachai, Pansakon, et al.
Publicado: (2023)

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions
por: Chang, Chih-Jung, et al.
Publicado: (2020)

Severe adverse drug reaction to allopurinol
por: Lucas, Grace, et al.
Publicado: (2022)

Identification of the novel HLA‐B*51:01:01:78 allele and confirmation of extended sequence of B*18:01:26
por: Ulrich, Silvia, et al.
Publicado: (2022)

Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and Phenytoin-Induced Cutaneous Adverse Drug Reactions in the South Indian Tamil Population
por: John, Shobana, et al.
Publicado: (2021)

HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients
por: Satapornpong, Patompong, et al.
Publicado: (2021)

Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy
por: Scavone, Cristina, et al.
Publicado: (2019)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

Characterization of a novel HLA-A*11:335 allele resulting from a rare interlocus recombination involving HLA-A*11:01:01:01/126 and HLA-H*02:07/14/18 alleles with nanopore sequencing, in a volunteer from the China Marrow Donor Program
por: Zhang, Li-Qun, et al.
Publicado: (2022)

Identification of the novel HLA‐DPA1*01:88 allele by next‐generation sequencing
por: Tiziana, Galluccio, et al.
Publicado: (2022)

Characterization of the novel HLA‐DQA1*01:89 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

Characterization of the novel HLA‐C*17:01:18 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

Characterization of the novel HLA‐DPB1*1348:01 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

A Novel Allele-Specific PCR Protocol for the Detection of the HLA-C*03:02 Allele, a Pharmacogenetic Marker, in Vietnamese Kinh People
por: Pham, Tran Thu Ha, et al.
Publicado: (2021)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
por: Somkrua, Ratchadaporn, et al.
Publicado: (2011)

Protective Allele for Multiple Sclerosis HLA-DRB1*01:01 Provides Kinetic Discrimination of Myelin and Exogenous Antigenic Peptides
por: Mamedov, Azad, et al.
Publicado: (2020)

Real-World Efficiency of Pharmacogenetic Screening for Carbamazepine-Induced Severe Cutaneous Adverse Reactions
por: Chen, Zhibin, et al.
Publicado: (2014)

HLA-A*33:01 as Protective Allele for Severe Dengue in a Population of Filipino Children
por: Mercado, Edelwisa Segubre, et al.
Publicado: (2015)

Characterization of the novel HLA‐DQA1*02:01:14 allele by sequencing‐based typing
por: Cargou, Marine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fn6ndcaaevsvf428e3im1otqua